NCT03017547View on ClinicalTrials.gov

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Acute Respiratory Distress Syndrome
Interventions
DRUG

IC14

Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS

OTHER

Placebo

sterile normal saline for infusion

Sponsors
All Listed Sponsors
lead

Implicit Bioscience

INDUSTRY